# Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE)

> **NCT06458972** · — · RECRUITING · sponsor: **Tongji Hospital** · enrollment: 139 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06458972
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12-31
- **Target enrollment:** 139 (ESTIMATED)
- **Last updated:** 2024-11-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06458972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06458972, "Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06458972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*